Nasopharyngeal Carcinoma
Conditions
Keywords
ultrasensitive PET CT
Brief summary
uEXPLORER total-body PET/CT in Nasopharyngeal Carcinoma
Detailed description
A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. The objective of this study is to determine its specific effect in newly diagnosed nasopharyngeal carcinoma compared with conventional PET/CT and the quantitative kinetic parameters including glucose metabolic rate (Ki), glucose transport rate of flow-in (k1) and flow-out (k2) between tissue and blood, and glucosamine-6-phosphatization rate in tissue (k3). All the neck lymph nodes suspected for metastatic in PET/CT were biopsied under the guidance of ultrasound for a pathological diagnosis.
Interventions
DEVICEultrasensitive positron emission tomography
A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER)
Sponsors
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Inclusion criteria
* Patients must be informed of the investigational nature of this study and given written informed consent. * Aged between 18-65, male/female. * Histologically confirmed non-keratinizing nasopharyngeal carcinoma (including differentiated type and undifferentiated type, WHO II and III).. * Fertile women should practice contraception during the study period. * HGB ≥90g/L ,WBC ≥4\*109/L , PLT ≥100\*109/L, * With normal liver function test (ALT and AST ≤2.5\*ULN, TBil ≤2.0\*ULN) * With normal renal function test (serum creatinine ≤1.5\*ULN)
Exclusion criteria
* Women in pregnancy or lactation * Patients with diabetes * Prior malignancy except adequately treated basal cell, squamous cell skin cancer, or cervical cancer in situ. * Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), and emotional disturbance. * Already involved in other clinical trial. * Mental disorder, civil disability, limited capacity for civil conduct.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The results of uEXPLORER Total-body PET/CT | 6 months | The Dynamic Imaging, Kinetic Parameters of uEXPLORER Total-body PET/CT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of uEXPLORER Total-body PET/CT and Conventional PET/CT | 6 months | Image quality and Static Lesion detectability of TB-PET/CT and conventional PET/CT |
| Protocol of TB-PET/CT in NPC | 6 months | Acquisition time and low dose simulation of TB-PET/CT |
Countries
China
Outcome results
None listed